These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 12435171

  • 1. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 2. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T, German Aranesp Study Group.
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [Abstract] [Full Text] [Related]

  • 3. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 May; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 4. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J.
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [Abstract] [Full Text] [Related]

  • 5. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 6. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Apr; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 7. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S, Boulton H, Gokal R.
    J Nephrol; 2004 Apr; 17(5):687-92. PubMed ID: 15593036
    [Abstract] [Full Text] [Related]

  • 8. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M, Hannedouche T, Fitte H, Cayotte JL, Urena P, Réglier JC, Groupe de l'étude NESP 20000117.
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [Abstract] [Full Text] [Related]

  • 9. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA, Harpe SH, Brophy GM.
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [Abstract] [Full Text] [Related]

  • 10. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y, Bárány P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ, European/Australian NESP 970200 Study Group.
    Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
    [Abstract] [Full Text] [Related]

  • 11. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
    Glaspy JA, Tchekmedyian NS.
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):23-9. PubMed ID: 12435170
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
    Hertel JE, Locay HR, Scarlata DS, Prathikanti R, Audhya PK.
    Mayo Clin Proc; 2006 Sep; 81(9):1188-94. PubMed ID: 16970215
    [Abstract] [Full Text] [Related]

  • 13. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK.
    Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445
    [Abstract] [Full Text] [Related]

  • 14. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.
    Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP.
    J Support Oncol; 2003 Feb 15; 1(2):131-8. PubMed ID: 15352656
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
    Hörl WH, Holzer H, Mayer GJ, Osterreichische Aranesp Studiengruppe.
    Wien Klin Wochenschr; 2002 Dec 30; 114(23-24):967-71. PubMed ID: 12635463
    [Abstract] [Full Text] [Related]

  • 16. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
    Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB.
    Cancer; 2003 Mar 01; 97(5):1312-20. PubMed ID: 12599240
    [Abstract] [Full Text] [Related]

  • 17. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul 01; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 18. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.
    Vansteenkiste J, Poulsen E, Rossi G, Glaspy J.
    Oncology (Williston Park); 2002 Oct 01; 16(10 Suppl 11):45-55. PubMed ID: 12435173
    [Abstract] [Full Text] [Related]

  • 19. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct 01; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 20. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Oct 01; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.